Idecabtagene vicleucel 用于复发/难治性多发性骨髓瘤：1 期试验的事后 18 个月随访

Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy.

We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (n = 62; median follow-up, 18. 1 months). The primary endpoint was safety outcomes, and secondary endpoints included overall response rate (ORR), complete response (CR) and very good partial response (VGPR). The study met its primary endpoint with low rates of grade 3/grade 4 cytokine release syndrome (6. 5%) and neurotoxicity (1. 6%). ORR was 75. 8%; 64. 5% achieved VGPR or better and 38. 7% achieved CR or stringent CR.

Among exploratory endpoints, median duration of response, progression-free survival (PFS) and overall survival were 10. 3, 8. 8 and 34. 2 months, respectively, and ide-cel expansion in blood and bone marrow correlated with clinical efficacy and postinfusion reduction of soluble BCMA.

Patients with PFS ≥ 18 months had more naive and less exhausted T cells in apheresis material and improved functional T cell phenotype in the drug product compared with those with less durable responses. These results confirm ide-cel safety, tolerability and efficacy and describe T cell qualities that correlate with durable response. Clinicaltrials. gov identifier : NCT02658929 .